Newsletter · 2026-07-03 · Ashutosh Agarwal

Biopharma M&A Supercycle and GLP-1 Momentum Lift a Historic Healthcare Rally - The Healthcare Pulse: Weekly Podcast Intelligence Brief - Week of June 26 to July 3, 2026

Healthcare had a historic week as the sector jumped 7% and biotech hit a five-year high, powered by an LOE-driven biopharma M&A supercycle, the July 1 launch of the Medicare GLP-1 'Bridge' pilot, and a maturing debate over AI drug discovery and China clinical-data credibility. Our synthesis for the week of June 26 to July 3, 2026.

The Healthcare Pulse

Week of June 26 to July 3, 2026: Biopharma M&A Supercycle and GLP-1 Momentum Lift a Historic Healthcare Rally

This Week at a Glance

Healthcare had a genuinely historic week: the S&P health care sector rose ~7% (vs. a ~2% drop for the broad S&P) and the XBI biotech index hit a five-year high, even as Bank of America flow data showed record client outflows earlier, a classic pain-trade rotation into a laggard, defensive group. Three storylines dominated the conversation on podcasts and the tape: (1) an accelerating biopharma M&A supercycle driven by patent-cliff (loss-of-exclusivity) math, with H1 2026 deal value hitting $106B across 201 transactions (Stocktwits); (2) the GLP-1/obesity franchise entering a new phase as the Medicare "Bridge" pilot launched July 1 with a $50/month copay; and (3) a maturing debate over AI in drug discovery and the credibility of China-originated clinical data.

The People Driving the Conversation

Evan Siegerman, BMO Head of Health Care Research, the week's most complete stock-level view, on Closing Bell Overtime (June 26). On the rotation and why deals matter: "the AbbVie acquisition of Apogee is definitely reigniting excitement. Other names have to buy. We talk about Merck in a lot of our recent research. We also point to Amgen, for example. All these companies have capacity to buy and will to do so." His discipline caveat: "the right deals get rewarded. The wrong ones get punished... if a company buys a company for just synergies, they're going to get punished." On his firm's favorite, Merck: "they have an LOE like all of their other peers with Keytruda going off patent later in the decade. And they've done a very credible job of... starting to refill that... I really like the Sedara acquisition... they had a pretty good ASCO with their SAC TMT data." His small-cap biotech pick was Ironwood (IRON), "multiple shots on goal, small cap name with a drug potentially on the market come next year."

Jerry Lee & Nick Richet, Global Co-Heads of Healthcare Investment Banking, J.P. Morgan, on Making Sense (June 26). Lee on the deal engine: "every single large-cap pharma is staring at a different set of LOEs... they need to fill all of these LOEs. So the cycle continues." He noted "the largest ever biotech follow-on for Revolutions Medicines... the largest ever biotech IPO for Kylara... the largest deal of the year, cross-border. That's Sun Pharma with Organon." Richet on AI's double edge: "AI is the reason why deals are getting done. It's also the reason why deals are not getting done... some businesses out there that have turned into show me stories."

Bob Kocher, Partner, Venrock, on Running Through Walls: Healthcare Prognosis 2026 (June 30), delivered the week's sharpest GLP-1 framing: "I think the GLP-1 market is going to end up looking as though the erectile dysfunction and cholesterol-lowering markets had a baby... So that's going to look like the old ED market where the rebates are like 60% or more... my bet is that the profit margin in the GLP-1 market gets squeezed pretty hard on both ends."

Liz Thomas (Head of Investment Strategy, SoFi) & Caleb Silver (Editor-in-Chief, Investopedia), on The Important Part (July 1), on the GLP-1 economy: "Right now, one in eight Americans is using a GLP-1," a market growing "at a 10% to 12% compound annual growth rate for the next 10 years." On the telehealth/compounding names (Hims & Hers, Ro): "those stocks are super volatile because they are trying to break into an industry where there is an 80% market share being held by Lilly and Novo... not all of them are going to make it."

Michael Kleinrock, IQVIA Institute, on The Astonishing Healthcare Podcast (June 26): the year's most astonishing data point was that GLP-1 patient volumes "basically doubled during the year of 2025... I didn't think it could keep accelerating," with "almost 200 obesity drugs in development."

David Reisinger (Leerink Partners), via CNBC's Annika Kim Constantino, on Squawk on the Street (June 30): "He expects Medicare coverage of obesity drugs to eventually rake in $1 billion in annual revenue for both Lilly and Novo," while cautioning the pilot "is temporary. It expires at the end of 2027."

The Key Debates

Debate 1. GLP-1: durable mega-franchise vs. margin compression / "bubble." Bull: Volumes doubled in 2025 (IQVIA, Astonishing Healthcare, June 26); the Medicare Bridge pilot opens millions of new patients at $50/month; Evaluate's 2026 World Preview projects Lilly's tirzepatide (Mounjaro/Zepbound) "will be worth over 70 billion dollars by 2032, making it the biggest drug ever" (via Citeline/Scrip, June 29). Bear: Venrock's Bob Kocher expects profit margins "squeezed pretty hard on both ends" as generics and 60%+ rebates arrive (Running Through Walls, June 30); and Deloitte flags obesity is now 38% of projected commercial inflows from the 2025 late-stage pipeline, a concentration risk (Zacks).

Debate 2. Biopharma M&A: structural "put" under mid-caps vs. platform bubble. Bull: JPM's Lee argues LOE-driven buyers are "relatively price insensitive... because the durability of these LOEs is just so large" (Making Sense, June 26); BMO's Siegerman notes AbbVie was rewarded (Apogee up ~17% on the week) for buying, a self-reinforcing signal (Closing Bell, June 26). Bear: average deal size is up 44% YoY to >$527M, feeding "platform bubble" concerns (Substack); JPM's Richet concedes velocity could stall "if inflation continues to worsen and we see rate hikes get pulled forward."

Debate 3. Novo Nordisk (NVO): value opportunity vs. value trap. Framed cleanly on Wall Street Wildlife (June 28) by a shareholder ("Badge"): NVO is "trading around 10 times earnings. And Eli Lilly is trading around 40 times earnings" after NVO fell "45% over the last year" (Cagrisema lost a February head-to-head vs. Lilly, wiping "$100 billion in market cap"). His own verdict captures both sides: "the bull and the bear case are kind of the same thing... you're buying a beaten down cheap company today. That property is always going to play second place to Eli Lilly." Evaluate's forecast that Novo's semaglutide products "slip outside the 2032 top 10" is the bearish long-tail (Citeline/Scrip, June 29); the buybacks (~$2.3B) and dividend are the value-holder's anchor.

Debate 4. "When the data has to travel": China clinical-data credibility. Centered on Summit Therapeutics (SMMT)/Akeso's ivonescimab, where ASCO HARMONi-6 showed an OS hazard ratio of 0.66 (StockTitan). Bull: FDA has accepted the BLA, PDUFA Nov 14, 2026. Bear: skeptics cite the 2022 FDA rejection of Lilly/Innovent's sintilimab and the risk that China-only benefit degrades in multi-regional populations (BioPharma APAC). BofA echoed the same caution on Merck's SAC-TMT, noting the Phase 3 OptiTrop-Lung06 is China-only and unlikely to support developed-market approval (MRK news, June 30).

Debate 5. Managed care: cheap defensive vs. structurally pressured. Bull: Morgan Stanley raised UNH to a $468 PT (Overweight, June 30), arguing it "should set a positive tone" for the July 16 managed-care earnings kickoff; JPMorgan's Street-high sits at $466 (Yahoo). Bear: the OBBBA Medicaid work-requirement deadline (Jan 1, 2027) threatens mass redeterminations; MACPAC has recommended CMS prohibit sole reliance on AI for adverse prior-auth decisions (higher admin cost); and a June 16 HHS OIG report flagged inaccurate Medicaid network directories at Centene, Elevance and UnitedHealthcare (HHS OIG). The bear on UNH is simply "priced-in" after a ~20% YTD run.

Hot Topics Under Debate (this week's buzz)

• AbbVie / Apogee (~$11B): The deal that "reignited excitement." William Blair's Matt Phipps called zumilokibat's efficacy "at least as good as the two entrenched biologics it will compete against, Sanofi/Regeneron's Dupixent and Eli Lilly's EBCLIS," with quarterly dosing (via Citeline/Scrip, June 29). AbbVie's tape was busy: Skyrizi pediatric approval, a positive Rinvoq CHMP opinion in alopecia areata, and positive Phase 3 EPCORE DLBCL-4 data (with Genmab).
• Eli Lilly at all-time highs: Hit $1,238 intraday (June 29) on GLP-1 momentum; also won a positive EU CHMP for Jaypirca (CLL) and was named to the FDA PreCheck domestic-manufacturing pilot (June 29).
• Sangamo Chapter 11: Selling assets to Lilly ($50M + liabilities: capsid, zinc-finger and integrase platforms + prion program) and Astellas ($25M + $25M milestones, Fabry gene therapy), a stark reminder that "times have been tough for gene therapy" (Citeline/Scrip, June 29).
• Amgen, a genuine red flag: The 2021 pivotal trial behind Tavneos (avacopan) was retracted from the NEJM (June 29) after the primary endpoint was re-adjudicated post-unblinding, amid an ongoing FDA investigation (NEJM). This is an earnings-quality / franchise-durability item worth watching, not a footnote.
• Guardant Health (GH): UnitedHealthcare began covering Guardant's Shield blood-based colorectal-cancer screening test (effective Aug 1), triggering a GH rally and multiple PT hikes (BTIG $190, Bernstein $200) (UHC policy).

Emerging Themes to Watch

• DTC/cash-pay channels breaking the PBM orthodoxy. IQVIA's Kleinrock: new distribution like "TrumpRx.gov" and direct shipment "do not fit into the orthodox pharmacy, PBM, medical insurer mix. They fit into something else." Combined with compounders and telehealth (Ro, Hims & Hers), this reshapes who captures GLP-1 economics.
• AI in drug development moving from hype to workflow. Executives converged on a pragmatic view: Genesis Molecular AI (partners GSK, Isomorphic) says AI's highest-leverage use is "selective molecules for well-understood targets" that beat the ~10% industry approval rate (Latent Space, July 1); Norstella's Suzanne Caruso says AI synthetic control arms can cut Phase 3 enrollment ~50% (Drug Discovery World, July 2); Dr. Reddy's chief cautioned AI "will not replace the science part of drug discovery... but will redefine the speed and scale" (Citeline, July 2).
• Policy as a deal variable. Most-Favored-Nation pricing and the COINS Act/BINSA outbound-investment screening are now actively shaping cross-border (especially China) deal structures, flagged directly by J&J, Sanofi and CSL executives at the BIO conference (via Citeline/Scrip, June 29).
• The "GLP-1 consumer" ripple trade. SoFi's Thomas and Investopedia's Silver traced knock-on effects: pressure on big-food CPG and alcohol, and tailwinds for protein/fiber, air fryers, and healthy fast-casual (Chipotle) (The Important Part, July 1).
• Private equity re-entry. JPM's Richet named PE's return as his single most-watched H2 item.

Stocks on the Radar

Directional tags reflect the balance of commentary heard this week, not a house recommendation.

Upcoming Catalysts (next ~2 weeks and key dated items)

Q2 dates for LLY, PFE, AMGN, ABBV, MRK, BMY, GILD were not individually confirmed this week; historically they report late-July to early-August. Only JNJ (Jul 15) and UNH (Jul 16) had firm in-week dates.

The Bottom Line

This was a "risk-on into a defensive sector" week, an unusual and telling setup. The money rotated into healthcare and biotech precisely because the group had lagged, and it found three real (not manufactured) narratives to hang on: an LOE-driven M&A cycle where buyers are being rewarded for spending, a GLP-1 franchise whose demand keeps compounding even as the smartest voices (Venrock's Kocher) warn the margins will eventually get squeezed on both ends, and an AI/China-data story that is maturing from slogan into a genuine underwriting question. The clearest asymmetry the tape offered: Lilly and AbbVie are the consensus quality longs (with valuation the only real bear point), Novo is the market's live value-vs-trap argument, and Amgen's NEJM retraction is the kind of quiet, existential-adjacent item that deserves more attention than it got. Into the next two weeks, JNJ (Jul 15) and UNH (Jul 16) will set the tone for whether this rotation has fundamental legs or was simply a positioning unwind.